Liver cancer

Below are current clinical trials.

Filter this list of studies by location, status and more.

1. Hepatocellular Carcinoma Early Detection Strategy Study

   Rochester, Minn.

   The purpose of this study is to evaluate the usefulness of new markers found in blood that might help to diagnose of liver cancer (HCC) early among people with cirrhosis. We hope that this study will show that these new markers could identify HCC at an earlier stage where better treatment options are available.

2. A Registry of Liver Tissue for Research

   Rochester, Minn.

   The purpose of the Hepatic Tissue Research Registry is to establish a local program to procure resected liver tissue and to gather critical patient and research information that will be utilized to develop a comprehensive biomedical database. This Registry data will be made accessible to scientists at Mayo, researchers outside of Mayo who have collaborations with Mayo researchers and to further biomedical and clinical research in liver biology, toxicology, cell transplantation, liver support therapy, and pathology.

3. A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma

   Scottsdale/Phoenix, Ariz., Jacksonville, Fla.

   This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of MEDI4736 in combination with tremelimumab, MEDI4736 monotherapy or tremelimumab monotherapy in subjects with unresectable hepatocellular carcinoma

4. A Study Comparing Vaccinia Virus Based Immune System Therapy Plus Sorafenib versus Sorafenib Alone to Treat Liver Cell Cancer

   Scottsdale/Phoenix, Ariz.

   The purpose of this study is to determine whether treatment with vaccinia virus based immune system therapy (Pexa-Vec) followed by sorafenib increases survival compared to treatment with sorafenib alone in patients with advanced liver cell cancer, who have not received prior systemic therapy.

5. Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer

   Rochester, Minn.

   This study is a prospective Phase IV study to determine if the use of Everolimus results in lower liver tumor recurrence and improved patient and graft survival after liver transplant for hepatocellular carcinoma (HCC). The immunosuppressive comparators will be Everolimus and Tacrolimus therapy compared to Tacrolimus and Mycophenolic acid/Mycophenolate Mofetil. Primary outcomes data is disease free survival (the time from randomization to HCC recurrence or death). Secondary outcomes are rate of recurrence of Hepatitis C, problems related to wound healing, hernia repair within the first 12 months, hepatic arterial thrombosis, renal function, acute cellular rejection, post-transplant diabetes, hypertension, and hyperlipidemia.

6. hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse

   Rochester, Minn.

   This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of six treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse.